NCT04789668 - Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

December 8, 2023

Study Completion Date

December 8, 2023

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Hematopoietic and Lymphoid Cell NeoplasmHormone Receptor Positive Breast AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Triple-Negative Breast CarcinomaPathologic Stage IV Cutaneous Melanoma AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

DRUG

Bintrafusp Alfa

Given IV

DRUG

Pimasertib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER